Arrowhead Research Corporation, a biopharmaceutical company developing targeted RNAi therapeutics, today announced that COO and Head of R&D, Bruce Given, M.D., presented data on the Phase 1 clinical study of ARC-520, the company’s clinical candidate for the treatment of chronic hepatitis B infection, at the HepDART 2013 conference being held on The Big Island, Hawaii.
http://www.news-medical.net/news/20131209/Arrowhead-accords-data-on-Phase-1-study-of-ARC-520-for-treatment-of-chronic-hepatitis-B-infection.aspx